Cargando…
557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
BACKGROUND: Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Hydroxychloroquine (HQN) is an experimental treatment for COVID-19. Effects of coadministration of HQN with RDV have not been studied and are relevant given the long half-lif...
Autores principales: | Arribas, Jose Ramon, Sanyal, Arun J, Soriano, Alex, Chin, Bum Sik, Kalimuddin, Shirin, Schreiber, Stefan, Elboudwarej, Emon, Tian, Yuan, Hyland, Robert H, SenGupta, Devi, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Lübbert, Christoph, Lye, David Chien Boon, Aberg, Judith A, Elorza, Enrique Navas, Tashima, Karen T, McPhail, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776163/ http://dx.doi.org/10.1093/ofid/ofaa439.751 |
Ejemplares similares
-
73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
por: Diaz, George, et al.
Publicado: (2020) -
548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19
por: Castagna, Antonella, et al.
Publicado: (2020) -
Molecular Epidemiology of Human Immunodeficiency Virus
por: Chin, Bum Sik
Publicado: (2017) -
Differences in clinical features and dengue severity between local and migrant Chinese with dengue infection in Singapore
por: Xu, Chuanhui, et al.
Publicado: (2018) -
Blood pressure trend in hospitalized adult dengue patients
por: Yeung, Wesley, et al.
Publicado: (2020)